Perfil clínico e laboratorial dos pacientes com Diabetes Mellitus tipo 2 em uso dos Inibidores do Cotransportador Sódio- Glicose 2 (ISGLT2) no Centro de Especialidades Médicas do CESUPA (CEMEC)

Abstract

Diabetes is a chronic systemic disease of great prevalence in Brazil that directly interferes with the quality of life of the population. Type 2 diabetes mellitus (DM2) is the most common type. The main complications in patients with DM2 are renal, cardiac and metabolic alterations. Aiming at the prevention of these complications, there are new therapeutic approaches that are safe and effective, such as sodium-glucose cotransporter 2 inhibitors (ISGLT2). Therefore, the study aimed to evaluate the clinical and laboratory profile of patients with DM2 using ISGLT2. For this purpose, a study was carried out, in which the methodology is based on a retrospective cross- sectional study, with the collection of data from the medical records of patients in the HIPERDIA, metabolism and nephrology outpatient clinics of the CESUPA Medical Specialties Center (CEMEC), from January to December 2023. The results evaluated demonstrate that of the 251 patients with DM2 evaluated at CEMEC, only 15% use the SGLT2 inhibitor. Furthermore, it was possible to evaluate the clinical profile related to the patients' existing comorbidities, presenting on average 78% of patients with hypertension and almost 99% with dyslipidemia. In addition, it was observed that there was no worsening of the parameters evaluated in laboratory tests such as glomerular filtration rate, blood glucose and glycated hemoglobin. Thus, this work demonstrates the impact of ISGLT2 on patients with DM2, through the analysis of the clinical and laboratory profile of these patients, contributing to better research development and prevention of systemic complications with the use of the SGLT2 Inhibitor.